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Several anti-tumour drugs exert some of their cytotoxic effects by
direct binding to DNA, thus inhibiting the transcription of
certain genes. We analysed the influence of the anti-tumour
antibiotic daunorubicin on the transcription of different genes in
io using the budding yeast Saccharomyces cereisiae. Dauno-
rubicin only affected wild-type yeast strains at very high concen-
trations; however, erg6 mutant strains (but not pdr1, pdr3 or pdr5
strains) were sensitive to daunorubicin at low micromolar
concentrations. In Derg6 strains, daunorubicin inhibited the
galactose-induced transcription by Gal4p in a specific manner,
since the transcription of identical reporters driven by other
activators (either constitutive or inducible) was not inhibited.
The drug concentrations at which Gal4p function was inhibited
INTRODUCTION
The anthracycline antibiotic daunorubicin (daunomycin) is
widely used in the treatment of cancer [1]. It accumulates in the
nuclei of living cells and intercalates into DNA quantitatively
[2–4], a property associated with some of the most relevant
effects of the drug: inhibition of DNA replication and gene
transcription both in io and in itro [5], displacement of protein
factors from the transcription complex in itro [6] and topo-
isomerase II poisoning [7]. Daunorubicin binds preferentially
(but not exclusively) to 5«-WCG-3« tracts [8,9]; such DNA
sequence specificity has led to the suggestion that daunorubicin
binding to DNA may interfere with the binding of transcription
factors to overlapping recognition sites. Thismodelwould explain
several effects of daunorubicin, such as inhibition of RNA
polymerase II in itro [10], inhibition of both DNA and
RNA synthesis in HeLa cells [11] and suppression of the co-
ordinate initiation of DNA replication in Xenopus oocyte extracts
[12]. A similar explanation would apply to the specific blocking
of transcriptional activation by other DNA-binding drugs, such
as distamycin A [13] or the bisanthracycline WP631 [6].
In this paper we dissect daunorubicin cytotoxicity in a cell
system amenable to rigorous genetic analysis, the yeast Sac-
charomyces cereisiae, which shares many common regulatory
mechanisms with vertebrates, ranging from cell cycle to trans-
criptional regulation [14]. The main setback to the use of
S. cereisiae cells in pharmacological studies is their resistance to
anti-tumour drugs [14,15], which is due to the strict permeability
barrier formed by the yeast cellular membrane. Here we tested
two genetic approaches to overcome this barrier. First, we used
yeast mutants deficient in the multidrug-resistance complex
(termed PDR in yeast), which expels a variety of chemical
Abbreviations used: Rap1p, repression/activation protein I ; RT, reverse transcriptase ; UAS, upstream activation sequence; UASgal, UAS of the GAL1-
10 gene promoter.
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did not affect cell growth or viability. Furthermore, daunorubicin
inhibited the growth in galactose and the transcriptional in-
duction of resident Gal4p-driven genes upon galactose addition,
two processes absolutely dependent on Gal4p function. We
propose that daunorubicin and some transcription factors com-
pete for DNA sequences encompassing CpG steps, and that this
is the main determinant of the effects of the drug on transcription
in io. Our approach may foster the development of anti-
tumour drugs with more specific mechanisms of action.
Key words: anthracycline, anti-cancer treatment, DNA-inter-
calating drug, ERG6, semi-quantitative reverse transcriptase
(RT) PCR.
compounds from the cell by a complex system of active membrane
transporters [16]. Secondly, we assayed a deletion of the ERG6
gene, which codes for an enzyme essential to the synthesis of
ergosterol and that renders cells sensitive to the topoisomerase I
inhibitor camptothecin and other drugs [15]. Our data showed
that daunorubicin was much more effective in Derg6 mutants
than in wild-type or PDR-deficient yeast strains.
DNA recognition sequences for some yeast transcription
factors contain CpG steps (where CpG refers specifically to the
sequence 5«-CG-3«), which constitute preferential binding sites
for daunorubicin. One of these factors is Gal4p, which recognizes
the interrupted palindromic sequence CGGN
""
CCG, known as
UASgal [the upstream activation sequence (UAS) of the GAL1-
10 gene promoter] [17], which includes two CpG steps. Gal4p is
a key yeast transcription factor of several genes involved in
galactose utilization, the GAL genes [18]. Expression of Gal4p is
repressed by glucose and constitutive when cells grow on other
carbon sources, like raffinose. In non-repressing conditions, GAL
genes become strongly activated upon galactose addition, in a
process that does not require de noo synthesis of Gal4p and that
depends on the functional suppression of a specific repressor,
Gal80p [18]. The control of GAL genes is a unique system to
analyse specific effects on transcriptional activation, since the
expression of the main regulator (Gal4p) and its ability to
activate transcription can be manipulated separately. Our finding
that daunorubicin specifically impaired Gal4p-driven promoters
(but not promoters that do not contain CpG steps) may explain
the specific inhibitory effects of daunorubicin on the transcription
of certain genes in io. To our knowledge, this is the first
report of a drug with a DNA-sequence-recognition site of only
3 bp that discriminates the cognate DNA sequences of distinct
transcription factors.
# 2002 Biochemical Society
132 S. Marı!n and others
MATERIALS AND METHODS
Yeast strains and plasmids
The yeast strain BY4741 (MATa ura3D0 leu2D0 his3D1 met15D0)
and its Dpdr1, Dpdr2, Dpdr5 and Derg6 derivatives were obtained
from EUROSCARF, Frankfurt, Germany. All reporter plasmids
are derivatives of pSFLD-178K, a multi-copy 2 lm yeast plasmid
that encompasses the CYC1 minimal promoter driving the
Escherichia coli b-galactosidase gene [19]. Sequences of the UASs
used in this study are shown in Table 1 and the resulting plasmids
are described elsewhere [19,20]. In all cases, oligonucleotides
encompassing the relevant sequences were inserted into the
unique KpnI site of pSFLD-178K. The expression plasmid
pH5HE0 contains the human oestrogen hormone receptor
HE0 [21] cloned into the constitutive yeast expression vector
pAAH5 [22].
Yeast transformation
The wild-type strain BY4741 was transformed following the
lithium acetate method [23]. The erg6 mutant, which does not
transform easily with this method, was transformed by electro-
poration, as described elsewhere [24].
Drug treatments
Daunorubicin was purchased from Sigma (St. Louis, MO,
U.S.A.). It was freshly prepared as a 500 lM stock solution in
sterile 150 mM NaCl, and diluted to the final concentrations
before use. Exponential growing yeasts were then exposed to the
different drug concentrations and incubated in the dark at 30 °C
for the times indicated.
b-Galactosidase assays
Cells carrying the plasmids were grown in selective media until
the late logarithmic phase. A suitable number of cells was then
transferred to microfuge tubes in 250 ll of YPD (5 g}l yeast
extract, 10 g}l peptone and 20 g}l glucose; all from Pronadisa,
Madrid, Spain), and the corresponding concentration of dauno-
rubicin was added. After incubation at 30 °C in a roller for the
indicated times, b-galactosidase assays were performed using
yeast protein extracts obtained with Y-PER (Pierce, Rockford,
IL, U.S.A.), as described elsewhere [25]. For galactose induction,
Derg6 cells transformed with plasmid pGAL were grown over-
night in YEP medium (identical to YPD but without glucose)
plus 2% raffinose. After adjusting the D
’!!
to 0.1–0.2, 1%
galactose was added together with daunorubicin. For oestrogen
induction, Derg6 cells transformed with pH5HE0 and pVITB2x
were grown in selective medium [6.7 g}l yeast nitrogen base
without amino acids (Difco, Basel, Switzerland) and 20 g}l
glucose, supplemented with 0.1 g}l prototrophic markers as
Table 1 Activating sequences and transcription properties of the plasmids
used in this study
Binding motifs are underlined; daunorubicin putative binding sites are shown in bold.
I, inducible; C, constitutive.
Plasmid Activating sequence Binding factor Type
pGAL TCGGAGGAGAGTCTTCCGAGT Gal4p I
pRPG2d TCGACACCCATACATTTACACACACCCATACATTT Rap1p C
pVITB2x AGTCACTGTGACC Oestrogen receptor I
required] and then transferred to YPD plus 1 nM oestradiol and
the indicated concentrations of daunorubicin.
RNA extraction and semi-quantitative reverse transcriptase (RT)
PCR
Total RNA was extracted from 50 ml yeast cultures by the hot
phenol method, as described elsewhere [26]. The samples were
treated as described in the Results section. RT-PCR was per-
formed using the OneStep PCR kit from Qiagen (Hilden,
Germany) following the manufacturer’s instructions. Sub-
saturating RT-PCR conditions were adjusted to 10 ng of total
RNA per reaction and to 25 amplification cycles. Tubuline
(TUB1) was used as a reference gene. Primers used were as
follows: TUB1 upper primer, 5«-AAGGGTTCTTGTTTACCC-
3«; TUB1 lower, 5«-GCCATGTATTTACCATCT-3«; GAL1
upper, 5«-CCAAGACCATTAGCCGAAA-3«; GAL1 lower,
5«-GACGGCGCAAAGCATATCA-3«; GAL3 upper, 5«-GGC-
CATAGATCCGTCTGTGT-3«; GAL3 lower, 5«-CTAGTGCT-
GCCGCGCAAGT-3«; GAL7 upper, 5«-GGTCAACAGGAG-
GCTGCTT-3«; GAL7 lower, 5«-CGAGCCTAACGGCAGC-
ATA-3«.
Sequence analysis
The sequence of yeast gene promoters and the identification of
the relevant regulatory sequences were obtained from the Sac-
charomyces Genome Database (http:}}genome-www.stanford.
edu}Saccharomyces}). The last visit made was on 23rd April
2002.
RESULTS
Sensitivity of yeast mutants to daunorubicin
Daunorubicin, like other DNA-intercalating drugs, affects wild-
type yeast strains at millimolar concentrations [27], which are
at least three orders of magnitude above pharmacological levels
Figure 1 Effect of daunorubicin on the growth of yeast cells with different
genetic backgrounds
Yeast BY4741 cells (+) and Derg6 (E), Dpdr1 (D), Dpdr3 (^) and Dpdr5 (V)
derivatives were treated for 16 h with various concentrations of daunorubicin. Drug effects on
growth are represented as the percentage of D600 reached by the treated culture relative to the
untreated control for each strain. Values represent means from two independent experiments,
with similar results.
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Table 2 Effect of daunorubicin concentration on yeast cell viability after
6 and 24 h of treatment
Viability is expressed as a percentage of total cells (means‡S.D. from four independent
experiments).
Viability (%)
Daunorubicin (lM) 6 h 24 h
0 100 100
3 74.9‡8.1 98.1‡12.3
10 54.0‡13.4 57.8‡23.9
25 48.0‡4.1 17.8‡6.5
50 36.2‡7.1 11.9‡7.2
Figure 2 Effects of daunorubicin on the transcription of reporter plasmids
The yeast Derg6 strain were transformed with the plasmids pGAL (+) or pRPG2d (U), or
co-transfected with the plasmids pVITB2x and pH5HE0 (D). Transformed cells were treated
with various daunorubicin concentrations for 6 h; for inducible systems, appropriate inductors
(galactose for the pGAL-transformed strain and oestradiol for the pVITB2x/pH5HE0 co-
transfected strain) were added simultaneously. Note that pGAL-transformed cells were grown
in raffinose prior to galactose addition to overcome glucose repression. Values represent
b-galactosidase activities relative to the untreated control. Values represent means from two
independent experiments, with similar results.
[28]. We explored the sensitivity to this drug of yeast mutants
with deficiencies in cell membrane permeability. The growth of
the wild-type strain was not inhibited at any of the daunorubicin
concentrations tested (up to 40 lM; Figure 1), whereas deletion
of the ERG6 gene (and thus lack of ergosterol in the yeast
membrane) increased the sensitivity to daunorubicin at low
micromolar concentrations (Figure 1). In contrast, deletion of
three key regulators of the yeast multidrug-resistance system
(Pdr1p, Pdr3p and Pdr5p) had no effect on the sensitivity of the
mutated strains to daunorubicin, even at concentrations up to
40 lM (Figure 1). As multidrug resistance in yeast requires the
function of the three PDR genes analysed [16], resistance to
daunorubicin in yeast cells should be mediated by exclusion of
the drug by the cell membrane rather than by excretion of the
drug to the medium through the multidrug-resistance system.
Growth inhibition of erg6 mutants by daunorubicin was
paralleled by a decrease in the proportion of viable cells in the
culture. Table 2 shows the proportion of viable cells in erg6
cultures treated with different daunorubicin concentrations for 6
or 24 h. Survival was about 50% at 10 lM daunorubicin in both
treatments.At higher drug concentrations, cell viability decreased
dramatically during the 24 h-exposure treatment. Hence, we
performed treatments for 6 h or less in further functional analyses
to reduce the influence of cell growth and cell viability on the
results.
Transcriptional inhibition by daunorubicin
The DNA-binding sequence for Gal4p (UASgal [17]) contains
two palindromic CGG repeats, which are also binding sites for
daunorubicin (Table 1). We thus explored the effect of the drug
on the ability of Gal4p to activate transcription. A synthetic
UASgal site was cloned in front of the minimal CYC1 promoter
fused to the lacZ gene coding sequence (plasmid pGAL; Table
1). This construct is silent in the presence of glucose and active
when cells grow in galactose, owing to the binding of Gal4p to
the UASgal. The transcription of pGAL in the presence of
galactose was highly sensitive to the presence of daunorubicin,
with an IC
&!
around 2 lM (Figure 2).
A major concern about the effects of DNA-intercalating drugs
on transcription is their pleiotropic nature. To show that the
effect of daunorubicin was neither due to a general malfunction
of the yeast cell nor to a non-specific decrease in b-galactosidase
activity, we tested the effect of daunorubicin on the constitutive
plasmid pRPG2d. This plasmid is identical to pGAL, except for
the replacement of the UASgal by two DNA-binding sites for the
ubiquitous factor repression}activation protein I (Rap1p;
pRPG2d, see Table 1 [19]). Daunorubicin did not affect the
transcription of the pRPG2d construct at concentrations up to
50 lM (Figure 2). This demonstrates that daunorubicin did not
affect b-galactosidase measurements or the enzymic activity of
b-galactosidase by itself.
However, a constitutive reporter may not be an adequate
control for an inducible promoter like UASgal. Therefore, we
took advantage of the ability of the mammalian oestrogen
receptor to activate transcription in yeast in an oestrogen-
inducible manner [29]. Unlike UASgal, the DNA-recognition
sequence for the oestrogen receptor, the oestrogen-responsive
element, does not contain CpG steps, the preferred DNA-
binding sites for daunorubicin [21]. Plasmid pVITB2x was
identical to pGAL, except for the substitution of the UASgal by
a canonical oestrogen-responsive element (Table 1). This reporter
construct is essentially silent in the absence of oestrogen, even
when an expression plasmid for the oestrogen receptor is co-
transfected into the same strain, but is strongly activated when
oestradiol is added to the culture [20]. The activation of pVITB2x
by oestradiol was not prevented by the simultaneous addition of
daunorubicin (Figure 2); therefore we conclude that the effects
of daunorubicin on the pGAL reporter transcription were
specific of the UASgal.
Specific inhibition of GAL genes by daunorubicin
A direct prediction from our reporter data is that daunorubicin
should prevent the activation of resident genes under Gal4p
control, the GAL genes. As these are essential for galactose
utilization, daunorubicin-treated cells should not utilize galac-
tose as a carbon source. Figure 3(A) shows that daunorubicin
concentrations as low as 200 mM prevented growth in a medium
in which galactose was the only carbon source, whereas growth
in glucose was inhibited only at daunorubicin concentrations
over 10 lM (see also Figure 1). These results indicate that
daunorubicin affected galactose utilization specifically.
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Figure 3 Effects of daunorubicin on galactose utilization
(A) Inhibition of growth in galactose. Derg6 yeast cells grown in glucose as a carbon source
(YPD) were transferred either to a fresh YPD medium (+) or to a YEP/galactose medium (D)
containing various concentrations of daunorubicin. Values on the y-axis represent relative cell
growth (taking the D600 of the untreated control as 1) after 16 h of incubation at 30 °C.
(B) Inhibition of activation of GAL genes by daunorubicin. Culture conditions are described at the
top of the panel. Daunorubicin concentration was adjusted to 3 lM. The picture shows semi-
quantitative RT-PCR products corresponding to GAL1, GAL3 and GAL7 genes. The constitutive
TUB1 gene is included as a reference. (C) Sequences of the UASgal sites in GAL1, GAL3 and
GAL7 promoters. Gal4p-recognition motifs (CGG) are underlined, whereas high-affinity dauno-
rubicin-binding sites (WCG) are marked in bold. SCG sites, which may also constitute
daunorubicin-binding sites, are found in several of these UASgal sequences.
The direct effects of daunorubicin on the transcription of
several GAL genes are shown in Figure 3(B). A single culture of
the Derg6 strain grown in raffinose was divided into three
identical cultures, which were incubated for 2 h either in 2%
raffinose, in a mixture of 2% raffinose and 1% galactose or in
the same raffinose}galactose mixture with the addition of 3 lM
daunorubicin. The three cultures grew at similar rates, as dauno-
rubicin had no effect on growth in raffinose at these con-
centrations (results not shown). Semi-quantitative RT-PCR
corresponding to TUB1-, GAL1-, GAL3- and GAL7-specific
primers revealed the virtual absence of GAL1 and GAL7 mRNAs,
and a low level of GAL3 mRNA in the raffinose-grown culture
(Figure 3B, left-hand lane). The addition of galactose strongly
induced the transcription of the three GAL genes (Figure 3B,
middle lane), which is consistent with the current model of
regulation of GAL genes [18]. However, the induction of these
genes by galactose was reduced when daunorubicin was added
simultaneously (Figure 3B, right-hand lane), especially for GAL1
and GAL7. Quantification of the bands in Figure 3(B) indicated
that daunorubicin reduced transcription of GAL1 and GAL7 to
39 and 29% of the untreated control value respectively. This
effect was somewhat lower than that observed for pGAL at the
same drug concentration (28%; Figure 2). The effect on GAL3
was clearly lower, down to 69% of the untreated control value.
Transcription of the housekeeping TUB1 gene was identical in all
three cultures. Figure 3(C) shows the Gal4p–DNA-binding sites
in the GAL1, GAL3 and GAL7 promoters, as well as high-affinity
sites for daunorubicin over the same sequences. As for the pGAL
reporter plasmid (Table 1), there is a clear overlap between the
DNA-recognition sequences for the transcription factor and for
the drug. The transcriptional activation of GAL genes by
galactose depends entirely on the binding of Gal4p to their
promoters [18]; therefore, these results sustain the proposed
specific inhibition of the Gal4p function by daunorubicin.
DISCUSSION
Identification of the appropriate targets of potential drugs to
improve the efficacy of anti-tumour targets on mammalian cells
in culture is complicated by the presence of multiple alterations
in these cells. These ill-characterized alterations include gene
mutations, chromosomal aberrations, unpaired metabolism and
failures of various steps of apoptotic pathways. Northern blot
experiments have revealed the effects of several anti-tumour
drugs on the steady-state levels of several mRNAs in cultured
mammalian cells [10,28]. However, the inherent complexity of
transcriptional regulation in higher eukaryotes makes it difficult
to differentiate the direct effects on the promoters from indirect
phenomena affecting the general metabolism of the cell. There-
fore, we used the yeast S. cereisiae to study the determinants of
the cell response to a particular cytotoxic effect, the inhibition of
transcription [14].
Standard laboratory yeast strains proved fairly insensitive to
daunorubicin at concentrations up to 50 lM, in agreement with
published data on the cytoxicity of several drugs in yeast [27]. We
found that only Derg6 strains, but not strains lacking the PDR
function, were sensitive to daunorubicin concentrations in the
therapeutical range. Derg6 strains are characterized by a severe
distortion of the cell membrane composition, due to the lack of
ergosterol. This suggests that the main factor protecting yeast
cells from intercalating drugs is their exclusion by the cell
membrane rather than the ability of the multidrug-resistance
system to expel the drugs from the cells. A similar conclusion was
reported for the topoisomerase I inhibitor camptothecin [15],
whereas multidrug-resistance systems seem to be the main
determinant of the resistance to anthracyclines in mammalian
cells [30]. Daunorubicin slightly affected yeast mitochondrial
DNA, as judged by the low rate of appearance of petite colonies
(results not shown), as described elsewhere [31].
Low concentrations (1–3 lM) of daunorubicin specifically
affected several processes related to galactose utilization and
Gal4p function in sensitive Derg6 yeast strains. For example,
transcriptional activation of the UASgal-based reporter pGAL
was very sensitive to daunorubicin, whereas transcription of the
related reporter plasmids pRPG2d and pVITB2x was unaffected
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by drug concentrations up to 50 lM. The minimal differences in
base sequence between these three constructs (short tracts of only
20–40 bp) make it unlikely that the different responses to
daunorubicin were due to differential plasmid stability or to
general effects on b-galactosidase transcription, translation or
enzymic activity. Our experimental design ensured that the
relevant transcription factors were present on daunorubicin
addition. Rap1p and the oestrogen receptor from pH5HE0 are
expressed constitutively [19,22], whereas Gal4p expression is
maximal in yeast cells growing in raffinose [18]. Therefore it is
highly improbable that the differential responses to the presence
of daunorubicin reported here are due to anything but a specific
effect of the drug on the respective UASs and on their recognition
by the relevant transcription factors.
Our data show the specific inhibition of Gal4p function at
different levels. Relatively low concentrations (1–3 lM)of dauno-
rubicin prevented the growth of yeast cells in galactose, which
requires Gal4p function, whereas they did not affect growth in
other carbon sources, such as glucose or raffinose, whose
utilization is independent of Gal4p [18]. Similar low concen-
trations of daunorubicin reduced the response of GAL1, GAL3
and GAL7 to galactose, which requires Gal4p binding to UASgal
sites present in their promoters [18]. The slight effect of dauno-
rubicin on the GAL3 response to galactose may be due to the low
induction of this gene by galactose (4-fold) when compared with
the very strong induction of either GAL1 or GAL7 [18].
Intercalating drugs can alter cell growth not only by producing
lesions on DNA, but also by preventing the binding of essential
transcription factors to DNA, as they may compete with the
factors for binding to DNA, provided their cognate sequences
coincide. We propose such a mechanism for the inhibition of
Gal4p-driven transcription by daunorubicin, since the drug and
Gal4p might compete for two crucial CpG steps in the UASgal
[17]. A similar mechanism has been proposed to explain the
inhibition of Sp1-activated transcription upon addition of anthra-
cyclines and bisanthracyclines in io and in itro [6,32] or the
inhibition of myogenic differentiation in cell cultures by other
drugs [13]. The lack of sensitivity of pVITB2x and pRPG2d to
daunorubicin is also consistent with this model, since the DNA-
recognition sites for the corresponding transcription factors (the
oestrogen receptor and Rap1p) do not contain CpG steps
(Table 1).
The finding that daunorubicin can discriminate between UASs
to inhibit gene transcription by RNA polymerase II is re-
markable, since it recognizes DNA tracts of only 3 bp in length.
To our knowledge, such a discriminatory capacity has been
unambiguously reported in io only for RNA polymerase III
genes using a ligand whose DNA-binding site is about 6 bp [33].
The development of small molecules with the ability to interfere
with the expression of specific genes in living cells may improve
the current therapies for human diseases [34,35], since they may
block specific pathways necessary for cell growth. This approach
may foster the development of new anti-cancer drugs with
alternative mechanisms of action.
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